21 September 2015 - An Indiana not-for-profit has bought back the rights to a tuberculosis drug it sold to a small drug company just three weeks ago, amid outcry after a hefty price increase by the company.

Rodelis Therapeutics had raised the price of the drug, Cycloserine, to $10,800 for a supply of 30 pills, up from about $480 that the Purdue Research Foundation had charged, the foundation said.

Purdue Research Foundation asked Rodelis to return the Cycloserine rights after learning about the price hike as well as the company’s failure to provide services to patients that would help them stay on the drug, said Daniel Hasler, the foundation’s president.

Rodelis posted a statement on its website confirming that it had returned rights to the foundation Saturday. Rodelis bought the rights on Aug. 19 and in a statement said it was in the process of putting in place a patient-assistance program to provide the drug at no cost to the uninsured. They said the cost for a patient taking the pills twice a day for a year would be $260,000 a year.

For more details, go to: http://www.wsj.com/articles/nonprofit-reacquires-rights-to-tuberculosis-drug-after-hefty-price-hike-1442879817?mod=asia&mod=djemITPA_t